XBiotech, Inc. (XBIT)

[ClayTrader]

* * $XBIT Video Chart 06-02-17 * *

Link to Video - click here to watch the technical chart video

[DownWithPumpers]

Adam is at it again: RTQ: 8.95 down 95 cents.

There's more turmoil to report at struggling XBiotech (XBIT) . The biotech company's No. 2 executive resigned last week.

Kelly Thornburg, XBiotech's senior vice president of operations, submitted his resignation letter on May 5 and left the company immediately. Thornburg's exit was disclosed in a note at the bottom of the XBiotech 10-Q filed with the Securities and Exchange Commission on Wednesday night.

https://www.thestreet.com/story/14130753/1/xbiotech-no-2-executive-resigns-leaving-struggling-biotech-without-top-operations-chief.html

[RISK-TAKER]

Feuerstein Is a JOKE!!! Has as many bad calls as good.. He himself is a great pumper/basher with his articles and tweets..
And I took a position on the drop for a swing trade ...
G/L

[DownWithPumpers]

XBIT down 40% to 10.19.

When people don't listen to Adam Feuerstein they lose money.

He pointed out last Summer, when XBIT was in the mid 20s, that XBIT didn't have a chance.

https://www.thestreet.com/story/13628326/1/xbiotech-cancer-drug-survival-claim-falls-apart-under-scrutiny.html

[stocktrademan]

XBIT bullish 16.90



















normal chart


log chart

[RISK-TAKER]

and out at $14.80...next..

[RISK-TAKER]

In here at 12.65 with a couple hundred shares..
Ride it a buck or two either way..
G/L

[TheFinalCD]

BIOTECH STOCKS WORTH CHASING: XBIOTECH, INC. (XBIT), ELEVEN BIOTHERAPEUTICS, INC. (EBIO)

XBiotech, Inc. (XBIT) ended last trading session with a change of 19.02 percent. It trades at an average volume of 198.66K shares versus 1.07M shares recorded at the end of last trading session. The share price of $24.9 is at a distance of 291.51 percent from its 52-week low and down 14.22 percent versus its peak. The company has a market cap of $676.78M and currently has 27.18M shares outstanding. The share price is currently 42.66 percent versus its SMA20, 64.26 percent versus its SMA50, and 104.68 percent versus its SMA200. The stock has a weekly performance of 37.11 percent and is 129.07 percent year-to-date as of the recent close.

On July 02, 2016 XBiotech Inc. (XBIT) presented positive results from a pivotal Phase III trial of Xilonix™, the company’s lead monoclonal (IgG1k) antibody immunotherapy for the treatment of advanced colorectal cancer (CRC). In the study, Xilonix-treated patients with advanced disease and multiple symptoms known to inversely correlate with overall survival experienced a 76% relative increase in clinical response rate (CRR), a novel measure of anti-cancer activity, after 8 weeks of therapy compared to placebo (33% vs. 19%, respectively; p=.0045). In addition, clinical response correlated with improved overall survival. Among responders (in both treatment and placebo arms), clinical response was associated with a 2.7-fold increase in overall survival (11.5 versus 4.2 months in responders vs. non-responders, respectively). Overall survival was not compared between treatment arms because after 8 weeks, all patients were eligible to receive study drug. Treatment with Xilonix was well tolerated, with an adverse event profile comparable to placebo. The data were presented at the 18th European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona, Spain.

Eleven Biotherapeutics, Inc. (EBIO) recently recorded 12.57 percent change and currently at $1.88 is 649 percent away from its 52-week low and down -76.5 percent versus its peak. It has a past 5-day performance of -12.15 percent and trades at an average volume of 3.38M shares. The stock has a 1-month performance of 5.62 percent and is -37.54 percent year-to-date as of the recent close. There were about 19.64M shares outstanding which made its market cap $36.92M. The share price is currently -10.05 percent versus its SMA20, 25.55 percent versus its SMA50, and 12.08 percent versus its SMA200.

On June 13, 2016 Eleven Biotherapeutics, Inc. (EBIO) announced that it has entered into an exclusive license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) relating to Eleven’s Interleukin-6 (IL-6) technology. Under the terms of the agreement, Eleven has agreed to grant an exclusive, worldwide license to Roche to develop and commercialize EBI-031, a humanized monoclonal antibody that potently binds IL-6 and inhibits all known forms of IL-6 cytokine signaling, currently being developed for the potential treatment of ocular diseases, and all other IL-6 antagonist antibody technology owned by Eleven.

Under the agreement, Eleven will be entitled to an upfront payment of $7.5 million, along with potential future milestone payments of up to $262.5 million. The first potential future milestone payment is subject to the effectiveness of an investigational new drug application (IND) for EBI-031. This first milestone payment will equal $22.5 million if the IND becomes effective on or before September 15, 2016 or $20.0 million if the IND becomes effective after September 15, 2016. In addition, Eleven could be entitled to receive royalties for net sales of potential future products containing EBI-031 or any other potential future products containing other Eleven IL-6 compounds. Effectiveness of the license agreement is subject to approval of the license by holders of at least a majority of the outstanding shares of Eleven’s common stock.

http://www.zergwatch.com/2016/07/05/biotech-stocks-worth-chasing-xbiotech-inc-xbit-eleven-biotherapeutics-inc-ebio/

[GALGO]

What was the problem today? there was plenty of opportunity to make some coin with XBIT. In @ 14.83 out @ 17.80

[courtpuppy]

Worst timing---EVER
Try to buy stocks that go up. That would be best.
I looked at your buys and sells in your profile.
Please let us know when you are ready to buy something else so we can all run away---FAST

[Tradescott818]

This is headed lower tomorrow don't get fooled

[GALGO]

Panic selling today, back to the $20's

[gregque]

got in 2 day

[venturecapp]

XBiotech’s Misfortune Could Be A Discounted Opportunity

http://marketexclusive.com/xbiotechs-misfortune-could-be-a-discounted-opportunity/1136/

[Tdash]

16++ ok

[Tdash]

14.30++++ that drop last week was a big discount

[Tdash]

looks like back to 13++

[venturecapp]

XBiotech’s Misfortune Could Be A Discounted Opportunity

http://marketexclusive.com/xbiotechs-misfortune-could-be-a-discounted-opportunity/1136/

[ThesT]

Late Friday PR? Not good.

[vectorinformatics]

Steinmeyer Law launches investigation into XBIT XBIT Class Action Homepage

[stocktrademan]

$XBIT recent news/filings

bullish



http://investors.xbiotech.com/phoenix.zhtml?c=253990&p=irol-irhome


## source: finance.yahoo.com

Thu, 03 Sep 2015 18:25:05 GMT ~ XBiotech Advances Phase 1/2 Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus

[at noodls] - 0 1 09.01.15 - XBiotech Advances Phase 1/2 Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus Company Begins Second Dosing Cohort in Dose ...

read full: http://www.noodls.com/view/9D608417956F1E5A96B8A7E2D2731EF41A5D9D7B
*********************************************************

Tue, 01 Sep 2015 11:00:00 GMT ~ XBiotech Advances Phase 1/2 Clinical Study of Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus Aureus

[GlobeNewswire] - AUSTIN, Texas -- XBiotech (NASDAQ:XBIT), the world's leading developer of next-generation True Human(TM) therapeutic antibodies, announced today the completion of the first cohort in its Phase 1/2 clinical ...

read full: http://finance.yahoo.com/news/xbiotech-advances-phase-1-2-110000369.html
*********************************************************

Mon, 24 Aug 2015 15:52:56 GMT ~ Edited Transcript of XBIT earnings conference call or presentation 28-Jul-15 12:30pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-xbit-earnings-conference-155256063.html
*********************************************************

Mon, 17 Aug 2015 15:33:08 GMT ~ XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe

[at noodls] - 0 1 08.17.15 - XBiotech (NASDAQ: XBIT), the world's leading developer of next-generation True Human™ therapeutic antibodies, announced today it has completed enrollment of the Company's pivotal, randomized ...

read full: http://www.noodls.com/view/69FB7C4EAD80644D19DC2AC21A15AE738FB6138C
*********************************************************

Mon, 17 Aug 2015 11:00:00 GMT ~ XBiotech Completes Enrollment for Xilonix(TM) Phase III Registration Study in Europe

[GlobeNewswire] - AUSTIN, Texas -- XBiotech (NASDAQ:XBIT), the world's leading developer of next-generation True Human(TM) therapeutic antibodies, announced today it has completed enrollment of the Company's pivotal, randomized ...

read full: http://finance.yahoo.com/news/xbiotech-completes-enrollment-xilonix-tm-110000347.html
*********************************************************

$XBIT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$XBIT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/XBIT/company-info
Ticker: $XBIT
OTC Market Place: Not Available
CIK code: not found
Company name: XBiotech Inc.
Incorporated In:
$XBIT share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$XBIT extra dd links

Company name: XBiotech Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=XBIT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=XBIT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=XBIT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/XBIT/news - http://finance.yahoo.com/q/h?s=XBIT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/XBIT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/XBIT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=XBIT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/XBIT
DTCC (dtcc.com): http://search2.dtcc.com/?q=XBiotech+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=XBiotech+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=XBiotech+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/XBIT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/XBIT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/XBIT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=XBIT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=XBIT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/XBIT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=XBIT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=XBIT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=XBIT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=XBIT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=XBIT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/XBIT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=XBIT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/XBIT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=XBIT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/XBIT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/XBIT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/XBIT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/XBIT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/XBIT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=XBIT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=XBIT



$XBIT DD Notes ~ http://www.ddnotesmaker.com/XBIT